Medtronic Reports Results of VenaSeal Closure System in VeClose Extension Study for Chronic Venous Diseases

Shots:

• The Veclose Extension study is a follow-on study of VeClose Study evaluating long-term outcomes at 5yrs. post-treatment with the VenaSeal Closure System in 56 patients with chronic venous disease resulted in 94.6% closure rate of the great saphenous vein (GSV)
• The VeClose Study involves assessment of VenaSeal & ClosureFast radiofrequency ablation (RFA) device demonstrating vein closure 91.4% & 85.2% respectively for 5yrs.
• The VenaSeal closure system is the non-tumescent, non-thermal, non-sclerosant procedure which utilizes a medical adhesive delivered endovenously to close the vein & eliminates the risk of nerve injury while treating saphenous vein

Click here to read full press release/ article | Ref: Medtronic | Image: Medtronic Endovenous